CTT Pharma Files PCT Application for Nanonized Cannabinoid

STONEY CREEK, ON / ACCESSWIRE / March 2, 2017 / CTT Pharmaceutical Holdings, Inc. CTTH, today announced the filing of an international patent cooperation treaty application (PCT), a milestone in its development of its patented platform of cannabinoid drug delivery systems. The PCT provides a unified procedure for filing patent applications to protect intellectual property in each of its member states, covering 151 participating countries. The filed PCT application addresses the use of the Company's fast dissolving, oral thin film technology (OTF) as the drug delivery system platform for cannabinoid ingredients, including, but not limited to: tetrahydrocannabinoid and analogs thereof, namely, delta-9 tetrahydrocannabinol (THC) and functionally equivalent compounds, including analogs and derivatives thereof such as: delta-8 tetrahydrocannabinol (D8-THC), tetrahydrocannabinol acid (THCA), tetrahydrocannabivarin (THCV), tetrahydrocannabivarin acid (THCVA) as well as cannabidiol (CBD), cannabidiol acid (CBDA), cannabinol (CBN), cannabigerol (CBG), cannabigerol acid (CBGA), cannabidivarin (CBDV), cannabidivarin acid (CBDVA), cannabinovarin (CBNV), cannabigerovarin (CBGV), cannabichromene (CBC) along with Opioids combined to reduce opioid consumption and the potential for resulting addiction. CTT's patent filing includes details that were previously submitted in four separate U.S. and Canadian applications, and includes numerous important broad patent claims and compounds, including novel opioids and other non-steroidal and steroidal drugs, THC and cannabidiol (CBD), as well as a variety of other phytocannabinoids and endocannabinoids. The PCT application was filed through Gowling WLG.

CTT's patented technologies and formulations have been tested in humans to demonstrate important benefits to consumers, including shortened time of onset and improved bioavailability for cannabinoid and opioids to treat many disorders such as chronic pain, PTSD, ADHD, anxiety, and sleeping disorders. CTT's patent applications are advancing as the Company continues to expand its patent portfolio with the strategy of owning the broadest and most important biotechnology formulations intellectual property portfolio relating to cannabinoids and other molecules such as opioids.

Dr. Pankaj Modi, Chairman and CEO of CTT stated, "We are excited to announce the filing of our PCT application as it is the next logical step in establishing and protecting our intellectual property on a global basis." Dr. Modi went on to say, "While our recently announced licensing agreement with CanniMed is the first step towards commercializing our technology in the Canadian markets, today's announcement positions us to continue to pursue developmental and commercial partnerships in the United States and internationally. I look forward to continuing to assess the various avenues to apply our technology to the rapidly growing and evolving medicinal and recreational cannabis industry. This is a significant milestone enabled by our team's discovery and production of a versatile new portfolio of cannabinoid pharmaceuticals."

CTT will have additional filings in the near future as our research continues and management focuses on treating these ailments as part of the Company's overall strategy. CTT has several other patent-pending applications in the U.S. and internationally, and believes it is well positioned for allowance of these additional patent claim sets.

About CTT Pharmaceutical Holdings

CTT Pharmaceutical is a world leader in developments of pain-free, non-invasive drug delivery systems to improve the overall quality of life for patients by providing safe, flexible, simple and innovative drug delivery systems for pain management therapies and treatments. CTT's overall mandate is to develop fast dissolving oral thin film wafers of opioids and medical marijuana for treatment of chronic pain, post-operative surgical pain, arthritis and joint pain and to treat many disorders such as PTSD, ADHD, anxiety, neurological and sleeping disorders.

CTT's principal asset is a unique and novel patented drug delivery technology, an orally administered, fast dissolving thin film (the "Wafer"). This technology platform will target both the human and veterinarian (pet) markets for treatment of many diseases including pain management. CTT's patents filing include details that were previously submitted in four separate U.S. and Canadian applications, and include numerous important broad patent claims and compounds, including novel opioids and other non-steroidal and steroidal drugs, THC and cannabidiol (CBD), as well as a variety of other phytocannabinoids and endocannabinoids through Gowling WLG.

CTT's oral fast dissolving drug delivery systems consists of thin films ("Wafers") that dissolve without water, within a few seconds after placement in the mouth. The majority of drugs administered using our drug delivery system mirror injections in that they have the ability to enter the bloodstream quickly, are convenient and discrete, and can be administered anywhere. A faster absorption rate is achieved because the mouth contains a very thin mucosa and is extremely vascular. There is no bitter taste, no smoke inhalation as is the case with cannabis, and less degradation of medication (by bypassing the stomach) and most importantly lower dosage units are required given the efficacy of absorption. Patient compliance is improved, especially with those who have a fear of choking and/or are pediatric, geriatric or incapacitated patients who have difficulty swallowing. Most fast dissolving systems on the market today deliver anti-inflammatories, antihistamines and cough and breathing related medications.

CTT believes that its Wafer technology will be one of the first to gain use in major markets such as pain management.

CTT has commenced the commercialization of its orally dissolvable thin film (ODF) wafer technology in Canada through a licensing relationship with CanniMed Therapeutics Inc., and is pursuing opportunities in various States within the U.S. and internationally.

For more information, please visit our website: www.cttpharmaceuticals.com

SOURCE: CTT Pharmaceutical Holdings, Inc.